Latest Conference Articles

Data published in Nucleic Acids Research builds on previous studies investigating the benefits of sarecycline for acne vulgaris compared to other antibiotics.

Click here to answer this week's poll.

Conferences provide valuable information and resources to help you grow in the dermatology space.

Updates from Incyte’s dermatology portfolio include late-breaking data on ruxolitinib cream and povorcitinib for vitiligo.

Study participants saw a rapid decrease in inflammatory lesions with the once-daily antibiotic, antibacterial, and retinoid gel.

Look back at 10 of the innovative sessions presented at the 2023 Winter Clinical Hawaii Conference in Kohala Coast, Hawaii.

From topical antibiotics like clindamycin to biologic injectables like adalimumab to surgical options like deroofing, treatment for HS can come in many forms.

Emmy Graber, MD, MBA, covered it all in her Winter Clinical Miami talk, offering take-home pearls via patient case studies.

With now more than 6 months of real-world use for baricitinib available, what challenges still remain for the alopecia areata treatment and what other agents are on the horizon?

Topicals, orals, biologics—Armstrong’s Winter Clinical Miami presentation focused on new treatment options for patients with psoriasis with an emphasis on real-world observations.

Alexandra Golant, MD, and Seemal Desai, MD, weigh the pros and cons of each treatment option for atopic dermatitis, considering mechanism of action, efficacy, and safety. Which will emerge victorious?

“So much new in the world of pediatric dermatology—new and novel treatments for atopic dermatitis, hemangiomas, childhood blistering diseases, warts. We are practicing during the Golden Age of dermatology,” Swanson says.

The proportion of patients who achieved a SALT score < 10 jumped from 24.9% at 36 weeks to 28.9% at 52 weeks in the BARI 4-mg arm and 11.8% to 15.3% in the BARI 2-mg arm.

When evaluating treatment options for patients with psoriasis, rosacea, or eczema, clinicians should employ a top-down approach and remember to consider topical therapies.

Five days of treatment with the topical therapy measurably improved symptoms and emotional/functional impact for patients with actinic keratosis at week 8.

“We're going to talk about medical hair loss in terms of diagnosis and treatment and really try to make it very easy,” Leavitt says.

From deucravacitinib to roflumilast to tralokinumab and everything in between, James Del Rosso, DO, previews his upcoming Winter Clinical Miami session on new therapies.

“It's always a fun, vibrant educational session. We learn tips and advice, and it really is for any injector, both novice [and] advanced. You learn a lot of information,” Ablon says.

“A lot of our colleagues are just getting used to the new biologics for atopic dermatitis like tralokinumab and dupilumab, which have really been breakthroughs in the treatment of atopic dermatitis,” Lebwohl, one of the co-founders of the Fall and Winter Clinical meetings, says.

With an emphasis on real-world applicability and actionable pearls, clinicians gather in Miami to kick off the newest addition to the Fall and Winter Clinical meeting lineup.

Mark Nestor, MD, PhD, a co-director of the Winter Clinical Miami meeting, promises attendees a hands-on learning experience with real-world applicability.

Discover all topics and sessions covered at South Beach Symposium.

Click here to answer this week's poll.

Catch up on coverage from the final day of South Beach Symposium.

A poster presentation from SBS 2023 reviewed the clinician satisfaction of tirbanibulin for the treatment of actinic keratosis.

Doris Day, MD, thoroughly discussed the up-and-coming topic of the gut-skin-brain axis related to healthy skin at SBS 2023.

Lio shares key highlights of his atopic dermatitis sessions at South Beach Symposium.

Alexis shares take-home points from his popular sessions at South Beach Symposium.